Lynch & Associates IN Has $14.72 Million Position in Johnson & Johnson (NYSE:JNJ)

Lynch & Associates IN cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 90,800 shares of the company’s stock after selling 651 shares during the period. Johnson & Johnson accounts for about 3.1% of Lynch & Associates IN’s investment portfolio, making the stock its 6th biggest position. Lynch & Associates IN’s holdings in Johnson & Johnson were worth $14,715,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of JNJ. Innealta Capital LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $27,000. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth approximately $43,000. Fairfield Financial Advisors LTD bought a new stake in shares of Johnson & Johnson during the second quarter worth approximately $46,000. Fairway Wealth LLC raised its stake in shares of Johnson & Johnson by 217.1% during the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock worth $49,000 after buying an additional 228 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Johnson & Johnson during the second quarter worth approximately $49,000. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $175.00 to $178.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. The Goldman Sachs Group lowered their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Thursday, October 10th. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.31.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $164.14 on Wednesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The firm has a fifty day simple moving average of $162.70 and a 200 day simple moving average of $154.52. The stock has a market capitalization of $395.02 billion, a price-to-earnings ratio of 10.23, a PEG ratio of 2.65 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.80 earnings per share. Research analysts forecast that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.